复星医药(02196.HK)子公司授出治疗多发性骨髓瘤药物开发等许可

阿斯达克财经
07 Feb

复星医药(02196.HK) 公布,控股子公司复宏汉霖就在研产品“HLX15”的静脉注射制剂与皮下注射制剂剂型,授予Dr. Reddy's于许可区域(即美国及英国、瑞士等42个欧洲国家)及许可领域内的开发、生产及商业化权利的许可。
据介绍,“HLX15”为复宏汉霖自主研发的达雷妥尤单抗生物类似药,拟用于治疗多发性骨髓瘤。截至去年11月,复星医药现阶段针对“HLX15”累计研发投入约为1.21亿元人民币。据本次合作约定,复宏汉霖将继续负责“HLX15”的研发并承担相应费用。(js/w)

(港股报价延迟最少十五分钟。沽空资料截至 2025-02-06 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10